Loyalty Program

Pfizer's Lipitor share slips, casting doubt on power of a loyalty program to save the brand

Pfizer's Lipitor share slips, casting doubt on power of a loyalty program to save the brand

By

Seven weeks after Pfizer's main Lipitor patent expired in the US, the drug is down to 32% market share and at least one name-brand analyst is casting doubt on the brand's survival strategy.

Email Newsletters